JP2023552852A5 - - Google Patents

Info

Publication number
JP2023552852A5
JP2023552852A5 JP2023535608A JP2023535608A JP2023552852A5 JP 2023552852 A5 JP2023552852 A5 JP 2023552852A5 JP 2023535608 A JP2023535608 A JP 2023535608A JP 2023535608 A JP2023535608 A JP 2023535608A JP 2023552852 A5 JP2023552852 A5 JP 2023552852A5
Authority
JP
Japan
Prior art keywords
gcc
seq
agent
heavy chain
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023535608A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552852A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/000852 external-priority patent/WO2022123307A1/en
Publication of JP2023552852A publication Critical patent/JP2023552852A/ja
Publication of JP2023552852A5 publication Critical patent/JP2023552852A5/ja
Pending legal-status Critical Current

Links

JP2023535608A 2020-12-09 2021-12-09 グアニル酸シクラーゼc(gcc)抗原結合剤の組成物及びその使用方法 Pending JP2023552852A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063123333P 2020-12-09 2020-12-09
US63/123,333 2020-12-09
PCT/IB2021/000852 WO2022123307A1 (en) 2020-12-09 2021-12-09 Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2023552852A JP2023552852A (ja) 2023-12-19
JP2023552852A5 true JP2023552852A5 (cg-RX-API-DMAC7.html) 2024-12-17

Family

ID=80119244

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023535608A Pending JP2023552852A (ja) 2020-12-09 2021-12-09 グアニル酸シクラーゼc(gcc)抗原結合剤の組成物及びその使用方法

Country Status (16)

Country Link
US (1) US20240033359A1 (cg-RX-API-DMAC7.html)
EP (1) EP4259165A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023552852A (cg-RX-API-DMAC7.html)
KR (1) KR20230130641A (cg-RX-API-DMAC7.html)
CN (1) CN117015388A (cg-RX-API-DMAC7.html)
AR (1) AR124289A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021397404A1 (cg-RX-API-DMAC7.html)
CA (1) CA3204692A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023001667A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023009126A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP23050865A (cg-RX-API-DMAC7.html)
IL (1) IL303541A (cg-RX-API-DMAC7.html)
MX (1) MX2023006773A (cg-RX-API-DMAC7.html)
PE (1) PE20240368A1 (cg-RX-API-DMAC7.html)
TW (1) TW202237639A (cg-RX-API-DMAC7.html)
WO (1) WO2022123307A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI861073B (zh) * 2019-03-21 2024-11-11 美商再生元醫藥公司 含有抗il-33抗體之穩定調配物
CN117720660A (zh) * 2022-09-19 2024-03-19 广东菲鹏制药股份有限公司 抗人鸟苷酸环化酶c抗体及其试剂盒和应用
AU2023349140A1 (en) * 2022-09-28 2025-04-03 Legend Biotech Ireland Limited Antibody and chimeric antigen receptors targeting gcc and methods of use thereof
CN115894697B (zh) * 2022-12-09 2023-08-29 华道(上海)生物医药有限公司 一种抗鸟苷酸环化酶2c的纳米抗体及其应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗hiv剤
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US6005079A (en) * 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
ES2257094T3 (es) 1998-11-03 2006-07-16 Centocor, Inc. Anticuerpos modificados y fragmentos de anticuerpo con duracion de actividad aumentada.
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
EP1274861B1 (en) 2000-03-27 2009-12-23 Thomas Jefferson University Compositions and methods for identifying and targeting cancer cells
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
EP1660186B1 (en) 2003-08-18 2013-12-25 MedImmune, LLC Humanization of antibodies
US20050042664A1 (en) 2003-08-22 2005-02-24 Medimmune, Inc. Humanization of antibodies
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
CA2542125A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
MY173390A (en) * 2009-10-23 2020-01-22 Takeda Pharmaceuticals Co Anti-gcc antibody molecules and related compositions and methods
US9156915B2 (en) * 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
US20190112380A1 (en) * 2016-03-29 2019-04-18 University Of Southern California Chimeric antigen receptors targeting cancer
PL3896091T3 (pl) 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
WO2019178580A1 (en) * 2018-03-16 2019-09-19 Thomas Jefferson University Anti-gucy2c chimeric antigen receptor compositions and methods

Similar Documents

Publication Publication Date Title
JP2017535257A5 (cg-RX-API-DMAC7.html)
JP2022512132A5 (cg-RX-API-DMAC7.html)
JP2021534762A5 (cg-RX-API-DMAC7.html)
JP2018506961A5 (cg-RX-API-DMAC7.html)
JP2026041845A5 (cg-RX-API-DMAC7.html)
JP2024518776A5 (cg-RX-API-DMAC7.html)
JP2023504003A5 (cg-RX-API-DMAC7.html)
JP2021514664A5 (cg-RX-API-DMAC7.html)
JP2020501598A5 (cg-RX-API-DMAC7.html)
JP2015172045A5 (cg-RX-API-DMAC7.html)
JP2019505564A5 (cg-RX-API-DMAC7.html)
JP2020510653A5 (ja) Ceaを標的にする多重特異性結合タンパク質
CN115551889A (zh) 抗cd73抗体及其用途
JP2021510521A5 (cg-RX-API-DMAC7.html)
JP2020510422A5 (cg-RX-API-DMAC7.html)
JP2017519501A5 (cg-RX-API-DMAC7.html)
JP2022535553A5 (cg-RX-API-DMAC7.html)
JP2020534830A5 (cg-RX-API-DMAC7.html)
JP2017526339A5 (cg-RX-API-DMAC7.html)
JP2024531409A5 (cg-RX-API-DMAC7.html)
JP2023543493A5 (cg-RX-API-DMAC7.html)
HRP20190605T1 (hr) Protutijela anti-fxi i postupci njihove uporabe
JP2023508174A5 (cg-RX-API-DMAC7.html)
JP2019528677A5 (cg-RX-API-DMAC7.html)
JP2025507817A5 (cg-RX-API-DMAC7.html)